CD19 and myeloid sarcoma: Preclinical trials in neurological disorders, in the experimental autoimmune encephalomyelitis (EAE) animal model of MS, and mouse models of MuSK MG and anti‐N‐methyl‐d‐aspartate receptor encephalitis have targeted specific antibodies instead of the entire population of cells expressing CD19 or BCMA with sustained treatment effects [41, 75, 76, 77].